Fortress Biotech (FBIO) – Zycubo (CUTX-101) FDA approval snapshot | Merlintrader trading Blog
FBIO • Rare disease / biotech

Fortress Biotech (FBIO)

Zycubo (ex CUTX-101) has been approved by the FDA as the first treatment for Menkes disease in pediatric patients – Cyprium/Fortress participate via milestones, royalties and a potential PRV.
FBIO chart – Finviz
Recent price (approx.)
~$4.4
Near 52-week highs
52W: $1.33 – $4.53
Merlintrader health score
3.0 / 5 – High risk biotech with new approved asset
Analyst target range (last 3–6 months)
$4.5
$17
Avg target: ~$10.7 • Range: $4.5–$17
Focus: FDA approval of Zycubo (copper histidinate, ex CUTX-101) as first treatment for Menkes disease in children – monetisation of milestones, royalties and a potential PRV for Fortress/Cyprium. Updated: Jan 13, 2026 (prices indicative)
Warning: ultra-rare indication, economics tied to diagnosis rates, access/pricing and execution by Sentynl/Zydus; FBIO’s upside is indirect and spread over time via milestones and royalties.
Language / Lingua

Why this name is moving

  • First FDA-approved treatment for Menkes disease: the FDA has approved Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients.
  • Fortress participates via Cyprium: under its deal with Sentynl/Zydus, Cyprium/Fortress are eligible for up to ~$129M in development and sales milestones, royalties of 3%, 8.75% and 12.5% on annual net sales tiers, and a potential Rare Pediatric Disease Priority Review Voucher (PRV).
  • From CRL to approval: the decision comes after a 2025 CRL focused on manufacturing (cGMP) issues – efficacy and safety data were not questioned, and the resubmission has now led to full approval.
Zycubo FDA approval – Menkes disease Milestones + tiered royalties + PRV for FBIO Ultra-rare / execution & access risk

What actually happened

Zycubo approval – what the FDA said

The U.S. FDA has approved Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients. The decision is based on two open-label, single-arm clinical trials including 66 treated children and 17 untreated controls, with treatment for up to three years. Early-treated children (therapy started within four weeks from birth) showed a 78% reduction in the risk of death versus controls; nearly half survived beyond six years and some more than 12 years, while no patient in the untreated group lived past six years.

How Fortress is economically exposed

Zycubo is developed and commercialised by Sentynl Therapeutics, a Zydus company. Under their agreement, Cyprium/Fortress:

  • are eligible to receive up to ~$129M in aggregate development and sales milestones from Sentynl;
  • receive tiered royalties on net sales: 3% of annual net sales up to $75M, 8.75% between $75M and $100M, and 12.5% above $100M;
  • retain ownership of any Rare Pediatric Disease PRV that may be issued on approval, which can be used on a future NDA or sold to a third party.

Fortress will therefore not record product sales for Zycubo directly, but benefits via milestones, royalties and potential PRV monetisation.

How the market is reading it

Price, range and profile

MetricValue (approx.)
Recent price~$4.4 per share
52-week range$1.33 – ~$4.53
Market cap≈ $130M (micro/small cap)
12-month performanceroughly +100–120% vs prior-year lows

The stock trades near its 52-week highs, but still close to the bottom of the analyst target band, reflecting both the positive regulatory outcome and an event-driven, high-risk profile at the holding-company level.

Analysts vs tape

Across major sources, the 12-month consensus target clusters around $10–11, with a range from roughly $4.5 to $17. At about $4.4, the stock sits near the low end of that range, implying theoretical upside if Zycubo cash flows and the broader Fortress pipeline are executed efficiently.

On social/retail channels, some traders frame the Zycubo approval as a “turning point” after the 2025 CRL; sceptics focus on the small patient population, Fortress’ complex structure and past dilution, and the lag between approval and meaningful cash inflows.

What to watch next (6–24 months)

From approval to real-world impact

  • Diagnosis & newborn screening: how quickly health systems identify Menkes infants early enough to benefit fully from Zycubo.
  • Access & reimbursement: payer decisions and on-the-ground access for families will shape the real commercial curve.
  • PRV monetisation: if/when Cyprium confirms receipt and potential sale or use of the Rare Pediatric Disease voucher.

For Fortress specifically

  • Milestone timing: visibility on which milestones are triggered at approval and the schedule for sales-based payments.
  • Use of cash: whether incremental cash flows de-risk the balance sheet or are mainly reinvested in new programmes.
  • Platform story: whether this success helps rebuild confidence in the Fortress “hub & spoke” model after past setbacks.
This snapshot focuses on why the Zycubo approval matters for FBIO. It is not a Buy/Sell verdict. Any concrete decision should be based on a full review of SEC filings, company presentations and your own risk tolerance.
Educational content only. This is not investment advice, not a recommendation to buy or sell any security, and not a substitute for your own due diligence or consultation with a licensed professional.
Personal note – position disclosure. At the time of writing I hold a small personal position in Fortress Biotech (FBIO). It is likely that I will close this position today, but this is not certain and I may decide to keep, reduce or increase it without further notice.

Further reading